Overcoming the Challenges of Conducting Early Feasibility Studies of Medical Devices in the United States

David Holmes, Robert Califf, Andrew Farb, Dorothy Abel, Michael Mack, Tamara Syrek Jensen, Bram Zuckerman, Martin Leon, Jeff Shuren

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Initial clinical studies of new medical technologies involve a complex balance of research participant benefits versus risks and costs of uncertainty when novel concepts are tested. The Food and Drug Administration Center for Devices and Radiological Health has recently introduced the Early Feasibility Study (EFS) Program for facilitating the conduct of these studies under the Investigational Device Exemption regulations. However, a systematic approach is needed to successfully implement this program while affording appropriate preservation of the rights and interests of patients. For this to succeed, a holistic reform of the clinical studies ecosystem for performing early-stage clinical research in the United States is necessary. The authors review the current landscape of the U.S. EFS and make recommendations for developing an efficient EFS process to meet the goal of improving access to early-stage, potentially beneficial medical devices in the United States.

Original languageEnglish (US)
Pages (from-to)1908-1915
Number of pages8
JournalJournal of the American College of Cardiology
Volume68
Issue number17
DOIs
StatePublished - Oct 25 2016

Fingerprint

Feasibility Studies
Equipment and Supplies
Radiologic Health
Patient Rights
United States Food and Drug Administration
Research
Uncertainty
Cost-Benefit Analysis
Ecosystem
Technology
Clinical Studies

Keywords

  • equipment design
  • new device development strategies
  • research design
  • research ethics committees
  • United States Food and Drug Administration

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Overcoming the Challenges of Conducting Early Feasibility Studies of Medical Devices in the United States. / Holmes, David; Califf, Robert; Farb, Andrew; Abel, Dorothy; Mack, Michael; Syrek Jensen, Tamara; Zuckerman, Bram; Leon, Martin; Shuren, Jeff.

In: Journal of the American College of Cardiology, Vol. 68, No. 17, 25.10.2016, p. 1908-1915.

Research output: Contribution to journalReview article

Holmes, D, Califf, R, Farb, A, Abel, D, Mack, M, Syrek Jensen, T, Zuckerman, B, Leon, M & Shuren, J 2016, 'Overcoming the Challenges of Conducting Early Feasibility Studies of Medical Devices in the United States', Journal of the American College of Cardiology, vol. 68, no. 17, pp. 1908-1915. https://doi.org/10.1016/j.jacc.2016.07.769
Holmes, David ; Califf, Robert ; Farb, Andrew ; Abel, Dorothy ; Mack, Michael ; Syrek Jensen, Tamara ; Zuckerman, Bram ; Leon, Martin ; Shuren, Jeff. / Overcoming the Challenges of Conducting Early Feasibility Studies of Medical Devices in the United States. In: Journal of the American College of Cardiology. 2016 ; Vol. 68, No. 17. pp. 1908-1915.
@article{52f3f20f28dc4db8bd9fd87b07e4c103,
title = "Overcoming the Challenges of Conducting Early Feasibility Studies of Medical Devices in the United States",
abstract = "Initial clinical studies of new medical technologies involve a complex balance of research participant benefits versus risks and costs of uncertainty when novel concepts are tested. The Food and Drug Administration Center for Devices and Radiological Health has recently introduced the Early Feasibility Study (EFS) Program for facilitating the conduct of these studies under the Investigational Device Exemption regulations. However, a systematic approach is needed to successfully implement this program while affording appropriate preservation of the rights and interests of patients. For this to succeed, a holistic reform of the clinical studies ecosystem for performing early-stage clinical research in the United States is necessary. The authors review the current landscape of the U.S. EFS and make recommendations for developing an efficient EFS process to meet the goal of improving access to early-stage, potentially beneficial medical devices in the United States.",
keywords = "equipment design, new device development strategies, research design, research ethics committees, United States Food and Drug Administration",
author = "David Holmes and Robert Califf and Andrew Farb and Dorothy Abel and Michael Mack and {Syrek Jensen}, Tamara and Bram Zuckerman and Martin Leon and Jeff Shuren",
year = "2016",
month = "10",
day = "25",
doi = "10.1016/j.jacc.2016.07.769",
language = "English (US)",
volume = "68",
pages = "1908--1915",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "17",

}

TY - JOUR

T1 - Overcoming the Challenges of Conducting Early Feasibility Studies of Medical Devices in the United States

AU - Holmes, David

AU - Califf, Robert

AU - Farb, Andrew

AU - Abel, Dorothy

AU - Mack, Michael

AU - Syrek Jensen, Tamara

AU - Zuckerman, Bram

AU - Leon, Martin

AU - Shuren, Jeff

PY - 2016/10/25

Y1 - 2016/10/25

N2 - Initial clinical studies of new medical technologies involve a complex balance of research participant benefits versus risks and costs of uncertainty when novel concepts are tested. The Food and Drug Administration Center for Devices and Radiological Health has recently introduced the Early Feasibility Study (EFS) Program for facilitating the conduct of these studies under the Investigational Device Exemption regulations. However, a systematic approach is needed to successfully implement this program while affording appropriate preservation of the rights and interests of patients. For this to succeed, a holistic reform of the clinical studies ecosystem for performing early-stage clinical research in the United States is necessary. The authors review the current landscape of the U.S. EFS and make recommendations for developing an efficient EFS process to meet the goal of improving access to early-stage, potentially beneficial medical devices in the United States.

AB - Initial clinical studies of new medical technologies involve a complex balance of research participant benefits versus risks and costs of uncertainty when novel concepts are tested. The Food and Drug Administration Center for Devices and Radiological Health has recently introduced the Early Feasibility Study (EFS) Program for facilitating the conduct of these studies under the Investigational Device Exemption regulations. However, a systematic approach is needed to successfully implement this program while affording appropriate preservation of the rights and interests of patients. For this to succeed, a holistic reform of the clinical studies ecosystem for performing early-stage clinical research in the United States is necessary. The authors review the current landscape of the U.S. EFS and make recommendations for developing an efficient EFS process to meet the goal of improving access to early-stage, potentially beneficial medical devices in the United States.

KW - equipment design

KW - new device development strategies

KW - research design

KW - research ethics committees

KW - United States Food and Drug Administration

UR - http://www.scopus.com/inward/record.url?scp=84993972109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84993972109&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2016.07.769

DO - 10.1016/j.jacc.2016.07.769

M3 - Review article

C2 - 27765194

AN - SCOPUS:84993972109

VL - 68

SP - 1908

EP - 1915

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 17

ER -